Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 44 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: High Risk for Pneumonia Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19

NCT04868903
View directory record Official record
Conditions
SARS-CoV-2 Infection
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,475 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 3:23 PM EDT
Terminated Phase 2 Interventional Results available

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

NCT04504032
View directory record Official record
Conditions
COVID-19
Interventions
Rivaroxaban, Placebo
Drug
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
18 Years and older
Enrollment
497 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Rogers, Arkansas • Los Angeles, California • San Diego, California + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Jul 22, 2026, 3:23 PM EDT
Withdrawn Not applicable Interventional

Paradoxical Response to Chest Wall Loading in Mechanically Ventilated Patients

NCT06093958
View directory record Official record
Conditions
ARDS, COVID-19, Mechanical Ventilation Pressure High, Ventilator-Induced Lung Injury
Interventions
Manual loading of the chest wall
Diagnostic Test
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Jul 22, 2026, 3:23 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years

NCT06029933
View directory record Official record
Conditions
Influenza, Community-acquired Pneumonia, Cardiovascular Events
Interventions
Adjuvanted Quadrivalent Inactivated Influenza Vaccine (aIIV4), High-Dose Quadrivalent Inactivated Influenza Vaccine (HD-IIV4)
Biological
Lead sponsor
Kaiser Permanente
Other
Eligibility
65 Years and older
Enrollment
960,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2023 · Synced Jul 22, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers

NCT04345653
View directory record Official record
Conditions
Covid19
Interventions
Hydroxychloroquine Sulfate (HCQ)
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Jul 22, 2026, 3:23 PM EDT
Recruiting Not applicable Interventional

REmotely Monitored, Mobile Health Supported Multidomain Rehabilitation Program With High Intensity Interval Training for COVID-19

NCT05218083
View directory record Official record
Conditions
COVID-19, Critical Illness, ICU Acquired Weakness, PICS, Cardiorespiratory Fitness
Interventions
REmotely monitored, Mobile health supported Multidomain Rehabilitation Program with High Intensity Interval Training (REMM-HIIT)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
Birmingham, Alabama • Lexington, Kentucky • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 22, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia

NCT04374565
View directory record Official record
Conditions
Corona Virus Infection, SARS-CoV 2, SARS Pneumonia, Pneumonia
Interventions
High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Jul 22, 2026, 3:23 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
3,082 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
71
States / cities
Cullman, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Jul 22, 2026, 3:23 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

NCT05327023
View directory record Official record
Conditions
Hematologic Neoplasms
Interventions
donor lymphocyte infusion, Cyclophosphamide, Busulfan, Mycophenolate mofetil, Fludarabine, Sirolimus
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 22, 2026, 3:23 PM EDT
Active, not recruiting Not applicable Interventional

HFIT Versus TENS Study for Chronic Low Back and Knee Pain

NCT05821530
View directory record Official record
Conditions
Chronic Pain, Knee Pain Chronic, Back Pain, Low
Interventions
HFIT, TENS, Control
Device · Other
Lead sponsor
Hinge Health, Inc
Industry
Eligibility
18 Years to 64 Years
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 7, 2023 · Synced Jul 22, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT04701658
View directory record Official record
Conditions
COVID-19
Interventions
Bamlanivimab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Jul 22, 2026, 3:23 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease

NCT06679140
View directory record Official record
Conditions
COVID-19 SARS-CoV-2 Infection
Interventions
ibuzatrelvir, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
2,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
84
States / cities
Little Rock, Arkansas • Bakersfield, California • Huntington Park, California + 62 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 3:23 PM EDT
Terminated Phase 2 Interventional

Study of the Safety, Tolerability and Efficacy of NP-101 in Treating High Risk Participants Who Are Covid-19 Positive.

NCT05785390
View directory record Official record
Conditions
COVID-19
Interventions
NP-101, Placebo
Drug · Other
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Miami, Florida • Berwyn, Illinois • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 22, 2026, 3:23 PM EDT
Withdrawn Phase 2 Interventional

A Placebo-Controlled Study of Auxora for the Extended Treatment of High- Risk Patients With Critical COVID-19 Pneumonia

NCT05171920
View directory record Official record
Conditions
Pneumonia
Interventions
Auxora, Placebo
Drug
Lead sponsor
CalciMedica, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Saint Paul, Minnesota • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Jul 22, 2026, 3:23 PM EDT
Completed Phase 1 Interventional

High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19

NCT04351620
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Jul 22, 2026, 3:23 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That Are Considered at Higher Risk of Severe COVID-19

NCT07222384
View directory record Official record
Conditions
COVID-19, SARS-COV-2 Infection
Interventions
BNT162b2 (2025/2026 formulation)
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
5 Years to 11 Years
Enrollment
343 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
27
States / cities
Palo Alto, California • San Diego, California • Hialeah, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Jul 22, 2026, 3:23 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

NCT04389840
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Interventions
Dociparstat sodium, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Loxahatchee Groves, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Jul 22, 2026, 3:23 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

NCT07266558
View directory record Official record
Conditions
SARS-CoV-2
Interventions
mRNA-1273, mRNA-1283, Placebo
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
50 Years to 64 Years
Enrollment
30,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
150
States / cities
Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jul 22, 2026, 3:23 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19

NCT04435808
View directory record Official record
Conditions
COVID-19
Interventions
Hydroxychloroquine
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 13, 2022 · Synced Jul 22, 2026, 3:23 PM EDT
Completed Phase 1 Interventional

Transfer of Infection Fighting Immune Cells Generated in the Laboratory to High Risk Patients With COVID-19 Infection

NCT04765449
View directory record Official record
Conditions
Covid19
Interventions
Cytotoxic T Lymphocytes
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jul 22, 2026, 3:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Testing for COVID-19 in High Risk Children With Intellectual and Developmental Disabilities (COV-IDD)

NCT04887129
View directory record Official record
Conditions
Covid19
Interventions
COVID-19 RT-PCR test, COVID-19 Vaccine Education Campaign
Diagnostic Test · Other
Lead sponsor
University of Rochester
Other
Eligibility
3 Years to 72 Years
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 22, 2026, 3:23 PM EDT
Active, not recruiting Not applicable Interventional Results available

Electrical Nerve Block for Amputation Pain

NCT02221934
View directory record Official record
Conditions
Post-Amputation Pain, Phantom Limb Pain, Residual Limb Pain, Stump Pain
Interventions
Altius
Device
Lead sponsor
Neuros Medical, Inc.
Industry
Eligibility
21 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
22
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Jul 22, 2026, 3:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

QuadraMune(TM) for Prevention of COVID-19

NCT04421391
View directory record Official record
Conditions
Covid19, Coronavirus, SARS-CoV 2
Interventions
QuadraMune(TM)
Dietary Supplement
Lead sponsor
Therapeutic Solutions International
Industry
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Oceanside, California
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Jul 22, 2026, 3:23 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.

NCT07445971
View directory record Official record
Conditions
COVID -19, COVID-19 (Prevention)
Interventions
MDX2301, Normal Saline
Biological
Lead sponsor
ModeX Therapeutics, An OPKO Health Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 22, 2026, 3:23 PM EDT